Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2001-04-13
2004-09-28
Foley, Shanon (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S022000, C435S239000, C435S325000, C435S367000
Reexamination Certificate
active
06797462
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates genetically modified cells, to an assay and methods and the usage thereof to measure the infectivity and viral resistant/sensitivity of isolate from peripheral blood mononuclear cells (PBMC) and plasma of an immunodeficiency virus. The present invention has utility in determining the HIV co-receptor usage, discovery of new drugs effective against HIV and monitoring a drug therapy protocol in order to enhance the effectiveness of drug treatment regimes against HIV-1 infection,
BACKGROUND OF THE INVENTION
There is currently no cost effective, “high throughput” method for analyzing the drug resistant phenotype of primary virus isolates derived from individuals receiving antiretroviral treatment. Various in vitro biologic and immunologic techniques have been developed to detect human and simian immunodeficiency viruses (HIV and SIV, respectively). These include assays that detect the enzymatic activity of the reverse transcriptase (RT) protein, ELISA based assays for the detection of HIV/SIV core antigen (HIV-1 p24 or HIV-2/SIV p27), direct quantitation of infectious virus by syncytial focus plaque assays or limiting dilution titration in susceptible host cells, visualization of virions by electron microscopy, in situ hybridization, and various nucleic acid-based assays. Recently, genetic reporter-based assays have been created to detect HIV/SIV infection. In this approach, mammalian cells are genetically modified to express a reporter gene such as &bgr;-galactosidase (&bgr;-gal), green fluorescent protein (GFP) or chloramphenicol acetyltransferase (CAT) in response to infection and Tat protein expression. These detection systems require enumeration of the number of infection-positive cells by flow cytometry or fluorescence microscopy (GFP), microscopy (&bgr;-gal), or the utilization of radioisotopes (CAT). The firefly luciferase gene, under control of the HIV-1 LTR promoter, has been used as a reporter gene for HIV-1 infection. Luciferase is very sensitive marker gene for HIV-1 infection, since expression of a relatively few number of luciferase molecules can result in appreciable activity levels using standard luciferase detection assays.
The sensitive detection of the virus quasispecies that comprise primary HIV isolates has proved difficult using immortalized CD4 positive cell lines. At least in part, this has been due to the lack of expression of the CCR5 chemokine co-receptor on the surface of such cell lines. The failure to detect infection of primary virus isolates (T-cell and macrophage tropic viruses) using immortalized cell lines has greatly impeded the development of useful approaches for detecting, quantifying and analyzing HIV infection of primary virus isolates. The present invention largely overcomes the prior art limitations.
REFERENCES:
patent: 5026635 (1991-06-01), Ferguson
patent: 5110906 (1992-05-01), Maddon
patent: 5126433 (1992-06-01), Maddon
patent: 5422274 (1995-06-01), Maddon
patent: 5443954 (1995-08-01), Reddel et al.
patent: 5532124 (1996-07-01), Block et al.
patent: 5670324 (1997-09-01), Littman
patent: 5800986 (1998-09-01), Haseltine et al.
patent: 5811282 (1998-09-01), Chesebro
patent: 5817767 (1998-10-01), Allaway
patent: 5837464 (1998-11-01), Capon et al.
patent: 6025154 (2000-02-01), Li et al.
patent: 6258527 (2001-07-01), Littman et al.
patent: 2002/0037281 (2002-03-01), Davidson et al.
patent: 2002/0037498 (2002-03-01), Hallowitz et al.
patent: WO 96/19495 (1996-06-01), None
patent: WO 97/28258 (1997-08-01), None
patent: WO 98/00535 (1998-01-01), None
patent: WO 99/23107 (1999-05-01), None
patent: WO 00/65356 (2000-11-01), None
Splenlehauer et al. Virology. 2001; 280: 292-300.*
Roos et al. Virology. 2000; 273: 307-315.*
Chackerian et al. Journal of Virology. 1997; 71 (5): 3932-3939.*
Lan, Y., et al., “A Direct Test for Zidovudine (ZDV) Resistance in Clinical Isolates of HIV,” Int. Conf. AIDS 1993, vol. 9, No. 1, pp. 476, Abstract No. PO-B26-2048.
Chackerian, B., et al., “Human Immunodeficiency Virus Type 1 Coreceptors Participate in Postentry States in the Virus Replication Cycle and Function in Simian Immunodeficiency Virus Infection,”Journal of Virology,May 1997, pp. 3932-3939, vol. 71, American Society for Microbiology, USA.
James, J., “T-20 and Trimeris”,Aids Treatment News,Apr. 1998, pp. 1-6.
Kilby, M., et al., “Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of gp41-Mediated Virus Entry,”Nature Medicine,1998, pp. 1302-1307, vol. 4 (11).
Kuhmann, S., et al., “Polymorphisms in CCR5 Genes of African Green Monkeys and Mice Implicate Specific Amino Acids in Infections by Simian and Human Immunodeficiency Viruses,”Journal of Virology,Nov. 1997, vol. 71(11), American Society for Microbiology.
Maddon, P., et al., The Isolation and Nucleotide Sequence of a cDNA Encoding the T Cell Surface Protein T4: A New Member of the Immunoglobulin Gene Family,Cell,1985, pp. 93-104, vol:42, College of Physicians and Surgeons, New York.
Platt, E., et al., “Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1,”Journal of Virology,1998, pp. 2855-2864, American Society for Microbiology.
Raport, C., et al., “Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine receptor (CCR5) for RANTES, MIP-1&bgr;, and MIP-1&agr;,”Journal of Biological Chemistry,1996, pp. 17161-17166, vol. 271(29), The American Society of Biochemistry and Molecular Biology, Inc. USA.
Rimsky, L., et al., “Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides,”Journal of Virology,1998, pp. 986-993, vol. 72 (2), American Society for Microbiology.
Black, R., et al., “Comparison of Methodologies for Detecting HIV Resistance,” Int. Conf. AIDS, 1991, Abstract No. W.A. 1078.
Japour, L., et al., “A Direct Test for Zidovudine (ZDV) Resistance in Clinical Isolates of HIV,” Int. Conf. AIDS, 1993, Abstract No. PO-B26-2048.
Jackson, C., et al., “Stavudine Sensitivities in Clinical HIV Isolates Obtained from a Pediatric Population,” American Pediatric Association and Society for Pediatric Research Annual Meeting, May 6-10, 1996, unnumbered abstract.
Wei, X., et al., “HIV-1 Selection in Response to Inhibition of Virus Fusion and Entry,” Abstract 611.
Deichmann, M. et al., “Expression of the Human Immunodeficiency Virus Type-1 Coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ Hematopoietic Progenitor Cells,”Blood,1997, pp. 3522-3528, vol. 89(10).
D'Souza, M. and Harden, V., “Chemokines and HIV-1 Second Receptors,”Nature Medicine,1996, pp. 1293-1300, vol. 2(12).
Hasler, J., et al., “A Rapid, Quantitative Bioassay Based on the Human Immunodeficiency VirusTrans-Activator,”Aids Research and Human Retroviruses.1989, p. 507-516, vol. 5(5).
Moore, J., et al., “Co-receptors for HIV-1 Entry,”Current Opinion in Immunology,1997, pp. 551-562, vol. 9(4).
Zella, D., et al., “Interferon-&ggr; Increases Expression of Chemokine Receptors CCR1, CCR3, and CCR5, But Not CXCR4 in Monocytoid U937 Cells,”Blood,1998, pp. 4444-4450, vol. 91(12).
Kappes John C.
Wu Xiaoyun
Alston & Bird LLP
Foley Shanon
UAB Research Foundation
LandOfFree
Cell-based assay for immunodeficiency virus infectivity and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell-based assay for immunodeficiency virus infectivity and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell-based assay for immunodeficiency virus infectivity and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3225963